Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
|
|
- Meredith Simmons
- 5 years ago
- Views:
Transcription
1 Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist Directorate responsible for Acute this Document Date of Implementation December 2014 Date Uploaded: 19 th January 2015 Review Date: 1 st January 2017 Clinical Guideline ID: CG0099 October 2014
2 CONTENTS PAGE 1.0 Introduction Aims of the Guidance Objectives of the Guidance Scope Competency Responsibilities of the Consultant Nephrologist Responsibilities of the Renal Dietitian Process for initiating or adjusting binder/vitamin D therapy 6 Appendix 1 Criteria for competence 7 Appendix 2 Supervised practice record 8 Appendix 3 Nutrition and Dietetic Service - letter 10 Appendix 4 Algorithm for phosphate binders 11 Appendix 5 Binder choice 12 Appendix 6 Algorithm for active vitamin D therapy 13 Appendix 7 Algorithm for vitamin D therapy 14 INTRODUCTION 2
3 THIS GUIDANCE MUST BE READ IN CONJUNCTION WITH THE RENAL ASSOCIATION GUIDELINES Patients with chronic kidney disease frequently develop an imbalance in calcium and phosphate blood levels. Evidence increasingly links inadequate serum phosphate control to higher morbidity and mortality in patients with Chronic Kidney Disease stage 5. Consistent control of the markers of bone metabolism and disease within published targets is a strong predictor of survival in dialysis patients and is now a key therapeutic goal in the treatment of CKD. Key elements to achieving acceptable blood levels in dialysis patients include the dietary restriction of phosphate, together with the use of phosphate binders to limit its absorption. The Renal Dietitian plays a key role in this process, assessing dietary phosphate intake and adherence to recommended medication. They assess tolerance of the various phosphate binders to the patient and identify problems with their use, as well as highlighting changes in calcium and phosphate levels that may require intervention to avoid significant symptoms and side effects. Responsibility for prescribing medication for renal patients lies with the General Practitioners on advice from Renal medical staff. This document outlines the specific criteria permitting appropriately skilled and competent Renal Dietitians to initiate and modify treatment with phosphate binders and vitamin D therapy for dialysis patients. 1.1 Aims of the Guidance Provide systematic guidelines allowing specified Renal Dietitians to contact GP s directly to suggest changes to phosphate binder and vitamin D therapy. To rationalise and expedite changes to phosphate binder medication prescription after the assessment of dietary phosphate intake and compliance with current binders by the Renal Dietitians, improving the efficiency of management of Mineral Bone Disease in dialysis patients. To achieve cost-effective control of calcium and phosphate blood levels. To improve the timeliness of the patient receiving the suggested change in treatment. To improve the patient experience. 1.2 Objectives of the Guidance 3
4 To maintain patients blood levels within the biochemical standards recommended by the Renal Association. To encourage patient adherence to phosphate dietary restrictions and bone medication. To provide an agreed hierarchy for the use of phosphate binders. To provide a framework for the timely monitoring of patients blood biochemistry: - Routine results to be reviewed monthly - Any change in medication to be actioned prior to the next month's bone biochemistry assessment. 1.3 Scope This protocol applies to Renal Dietitians employed in the SHSCT, who have been deemed competent by the Lead Bone Management Nephrologist. This protocol applies to Adult patients with end-stage renal failure requiring phosphate binders and/or vitamin D therapy who are receiving dialysis. Advice from the Consultant Nephrologist should be sought for those patients where: Phosphate remains above target despite maximum tolerated binder therapy Calcium level is > 2.55 mmol/l or < 2.10 mmol/l Agree to adhere to more than maximum binder therapy indicated in this protocol Require initiation of calcimimetic therapy or where a change in calcimimetic therapy is required PTH remains > 500 pg/ml or more than 300pg/ml and rising Are post para-thyroidectomy until Calcium levels ave stabilised Are pregnant or under 16 years. 2.0 Competency Renal Dietitians who have been qualified at least 5 years, with > 2 years experience working with dialysis patients, Band 6 or above and have completed competency based training in the use of the protocol and satisfactory supervised practice (Appendices 1 & 2). Evidence of competence and supervised practice should be held within the dietetic department/renal unit along with the individual Dietitians supervision notes. It is the responsibility of the Dietitian to ensure that they are competent and to inform their line manager of any further training needs. The Consultant Nephrologist will continue to assess competency during the 3 monthly MBD joint meetings. 4
5 If none of the Renal Dietitians specified to use this protocol are available; responsibility for the management of CKD-MBD reverts to the Renal medical team. 3.0 Responsibilities of the Consultant Nephrologist The Lead Bone Management Nephrologist will: Ensure the Dietitians working within this protocol have completed supervised practices which deem them competent in following this protocol. In combination with the Renal Dietitians, will ensure the bone protocol remains up to date and evidence based. The protocol will be reviewed yearly. Supervise the practice of Dietitians following this protocol by continuing bone management meetings every 3 months with the Dietitian. 4.0 Responsibilities of the Renal Dietitian The Renal Dietitian will: Work within the scope of this protocol. Ensure practice/knowledge is up to date by providing evidence of continued professional development. Provide regular updates to the professional manager as part of the supervision procedure. Actively engage in supervised practice with the Consultant Nephrologist. Monitor and evaluate this protocol, to include: improved timescales for patient receiving prescription charges (currently can take up to 8 weeks) biochemistry results patient satisfaction 5
6 5.0 Process for initiating or adjusting binder/vitamin D therapy. Review of biochemistry, dietetic assessment (see dietetic care pathway) Follow appropriate algorithm depending on assessment - Appendices 4-7 Agree treatment plan with patient Complete GP letter using standard letter for suggested treatment (Appendix 3) Document suggested medication changes on emed (Dietitian and clinical meeting note) (Following SHSCT dietetic record keeping guidance) Issue letter to patient who will take to GP or post to GP (depending on patient preference) who will issue script Update medication list on emed Check patient has received script, can tolerate new medication and is taking as directed (within 1 week, not more than 2 weeks) 6 Review bone biochemistry/changes at monthly bloods/bone management meeting
7 Appendix 1 CRITERIA FOR COMPETENCE End Competence: To be competent in suggesting to the patients GP, appropriate type and dose of phosphate binding medication and vitamin D therapy for maintenance haemodialysis patients. Name of Renal Dietitian Name of Supervisor /s :... :.... Competency Assessment 5 years post registration experience 2 years dialysis renal experience Band 6 or above Demonstrates a knowledge of: CKD-MBD Interpretation of calcium, phosphate and PTH blood results Other medications which can effect Ca, PO4 and PTH levels Scope of this protocol Binders included in this protocol, including contraindications, maximum doses, side effects, Calcium content and potential drug interactions The role of Vitamin D Incident reporting process Date Supervisor signature Date competency assessment completed: / /. Signature of Supervisor.. Designation.. Copies of completed competency and supervised practice forms to be kept in the Nutrition and Dietetic Dept, as part of the individual Dietitians supervision notes 7
8 Appendix 2 SUPERVISED PRACTICE RECORD - Clinical assessment - Consultant Nephrologist The candidate is to review and present suggested changes to the Consultant Nephrologist for dialysis patients, as part of assessment, following monthly bloods/preparation for bone management meetings. The patient s biochemistry is to be evaluated and the treatment plans recommended by the Dietitian are to be discussed and reflection encouraged. Name of Renal Dietitian: Date Summary of patient biochemistry and medication Changes suggested by Dietitian Comments from Nephrologist Competent Yes/No 8
9 Date Summary of patient biochemistry and medication Changes suggested by Dietitian Comments from Nephrologist Competent Yes/No Date sufficient satisfactory supervised practices completed: / /. Signature of Supervisor.. Designation.. Copies of completed competency and supervised practice forms to be kept in the Nutrition and Dietetic Dept. as part of the individual dietitians supervisi 9
10 Appendix 3 Nutrition and Dietetic Service This letter is sent from a non-prescriber Name: Address: This copy for General Practitioner Write Clearly and use ballpoint Hospital: Clinic: DOB: H&C number: Dear Dr: This patient was seen on. A suggested change in treatment is shown below Diagnosis /Problems Treatment given to. Treatment to be discontinued SUGGESTED NEW TREATMENT Dose and frequency (Approved Units) Route Length of course Bone biochemistry will be monitored at Haemodialysis Unit For information only - no GP prescribing required drug below provided by hospital New treatment administered on Haemodialysis unit Dose and Frequency Route Length of course This letter is sent from a non-prescriber. Please consider suggested treatment before issuing a prescription Suggested GP follow up / investigations Signature Name in Capitals Registered Dietitian Review arranged: Yes No Date: / / Clinical letter to follow Yes No Contact phone no: 10
11 Algorithm for phosphate binders Appendix 4 Check bone biochemistry Po4 1.1 mmol/l Po mmol. Po4 1.5 mmol/l Assess dietary intake and review need for binders Review monthly bloods Nutritional Assessment Check bone medication prescription and compliance Calculate average Po4 over 3 months Aver PO4 < 0.9 mmol/l Stop binders Aver PO mmol/l Reduce binders by half Calcium < 2.0 mmol/l Calcium mmol/l Look at calcium trend, vascular history, Dca. Seek advice from Consultant Po4 intake < 1000 mg per or nonadherence with diet or requires /change binders Suggest binder (see guidance on pg 12 ) Advise re: Diet and/or timing of binders based on PO4 dietary load Calcium >2.6 mmol/l Reduce Dca and Seek advice from Consultant Po4 intake high or nonadherence to recommended bone medication Advise re: low po4 diet +/- distribution of binders. Review monthly bloods Review monthly bloods October 2014
12 Appendix 5 Binder choice: 1st line binders Calcium Acetate Maximum dose Exclusions: Inclusions Renacet 950mg 7 tablets per CV disease Calcium > 2.55mmol/ Patient prefers to swallow Renacet 475mg 14 tablets per Phosex 1g 6 tablets per CV disease Calcium > 2.55mmol/ Patient prefers to swallow Phoslo 667mg 9 tablets per CV disease Patient prefers to swallow Osvaren 435mg calcium acetate + 235mg MgCO 3 October tablets per Calcium > 2.55mmol/ Mg > 2 mmol/l Check Mg levels 3 monthly and stop if Mg > 2 mmol/l Calcium > 2.55mmol/ 2 nd line binders Calcium Carbonate. Maximum elemental calcium load 1500mg Maximum dose Exclusions: Inclusions Adcal 600mg 3 times per CV disease Diabetes History of high Ca PO 4 average > 2.0mmol/L PTH <150 3 rd line binders Non calcium based binders Maximum dose Exclusions: Inclusions Renvela 800mg Sevelamer 15 tablets per carbonate Renvela sachets 2.4g Sevelamer carbonate Renagel 800mg Sevelamer hydrochloride Fosrenol 500 mg, 750 mg, 1000mg Lanthanum Fosrenol Sachet 750mg, 1000mg sachet Alucaps 475 mg Aluminium hydroxide 3 sachets per 15 tablets per 4500mg per 4 sachets per Bowel obstruction Bowel perforation GI disorders Dysphagia Bowel obstruction Bowel perforation GI disorders Bowel obstruction Bowel perforation Dysphagia GI disorders Inflammatory bowel disease, bowel obstruction Acute peptic ulcer Dysphagia Inflammatory bowel disease, bowel obstruction Acute peptic ulcer 6 per check Al level 3 monthly, stop if Al level is > 20 µg/l; Only on advice from Consultant Patient prefers to swallow Patient prefers to chew tablet Calcium >2.55 mmol/l Patient prefers to swallow Able to take larger number of tablets Eating habit - grazes Calcium >2.55 mmol/l Patient finds swallowing tablets difficult Dissolved in 60mls water Calcium >2.55 mmol/l Patient prefers to swallow Able to take larger number of tablets Eating habit - grazes Calcium >2.55 mmol/l Patient prefers to chew Prefers to take less tablets Eats only 3 times per Patient finds chewing tablets difficult. Spread on food Calcium >2.55 mmol/l PO4 poorly controlled despite adherence to Sevelamer
13 Algorithm for Active vitamin D therapy Appendix 6 Check monthly bloods consider trend in PTH PTH checked 3 monthly or monthly for PTH > 500 or on calcimimetics. PTH < 130 pg/ml PTH pg/ml and stable PTH >300, or 130 and rising PTH > 500pg/ml On Calcitriol Po4 1.7 mmol Po4 >1.7 mmol Discuss with consultant No Calcitriol Weekly dose < 750ng Weekly dose > 750ng Repeat PTH in 3 months Ca < 2.1 mmol/l Ca mmol/l Ca mmol/l Ca >2.5 mmol/l Discuss with consultant at 3/12 meeting Stop Calcitriol Repeat PTH in 3 months Reduce weekly Calcitriol dose by ½ Commence on Calcitriol 250 ng daily; Discuss with consultant if Ca <1.9 (consider higher Dca) Commence on Calcitriol 250 ng daily or Calcitriol dose by 1/3 Reduce Dca to next lowest available Commence on Calcitriol 250 ng 3/7 or Calcitriol dose by 1/3 Reduce Dca to next lowest available and discuss with consultant Repeat PTH in 3 months October 2014
14 Algorithm for Vitamin D therapy Appendix 7 Check Vitamin D status Vitamin D < 70 nmol/l Vitamin D nmol/l Vitamin D > 145 nmol/l Vitamin D <35 nmol/l Vitamin D 35 to 69 nmol/l No action required Seek advice from consultant for reduction in Colecalciferol Start 80,000 units each HD x 3, then 40,000 units colecalciferol weekly Start 20,000 units colecalciferol weekly (if vitamin D <50 load 80,000 units each HD x 3 initially) Re check vitamin D in 6 months October 2014
Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
This is an official Northern Trust policy and should not be edited in any way Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Reference Number: NHSCT/12/553 Target
More informationClinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationNOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT Phosphate Binders for the Treatment of Hyperphosphataemia in adults with Chronic Kidney Disease OBJECTIVES To outline referral
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationChronic Kidney Disease Mineral Bone Disease
NHS Logo here Chronic Kidney Disease Mineral Bone Disease (CKD-MBD) Patient Information Health & care information you can trust The Information Standard Certified Member Working together for better patient
More informationMedicines for anaemia and mineral bone disease
Patient Information: Medicines NHS Logo here Medicines for anaemia and mineral bone disease Health & care information you can trust The Information Standard Certified Member Working together for better
More informationGreater Manchester Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
Greater Manchester Guidelines on the Management of (CKD-MBD) Classification: Clinical Guideline Lead Author: Smeeta Sinha, Consultant Nephrologist Additional author(s): Elizabeth Lamerton, Renal Pharmacist
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationLiterature Scan: Phosphate Binders
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationKent Kidney Care Centre: Medicines prescribed for people with chronic kidney disease
Kent Kidney Care Centre: Medicines prescribed for people with chronic kidney disease Information for patients The following pages offer you information on some of the medicines that you may need. It is
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMN.04 Effective Date: 11.15.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCommon Medication for People Receiving Haemodialysis
Common Medication for People Receiving Haemodialysis Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm
More informationVelphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More informationCG1339. Version: Renal Services Group. Approving forum (QIPS or equivalent):
University Hospitals Coventry & Warwickshire NHS Trust Clinical Guideline (full) CHRONIC KIDNEY DISEASE (CKD) NUTRITIONAL RECOMMENDATIONS FOR PERITONEAL DIALYSIS E-Library Reference CG1339 Version: Approving
More informationThink about phosphate step 1
Think about phosphate step 1 Phosphate (PO 4 ) is a mineral that your body needs to make healthy bones and tissues. Your kidneys control the amount of phosphate that is excreted in the urine. When your
More informationNottingham Renal and Transplant Unit
Nottingham Renal and Transplant Unit Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationCOMMON MEDICINES USED IN CKD CHRONIC KIDNEY DISEASE
CHRONIC KIDNEY DISEASE 1 This information is intended to help you understand why you need to take your medicines. There are multiple medicines that are used to control the symptoms related to CKD. You
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationGUIDELINES FOR MAINTAINING SERUM CALCIUM FOLLOWING PARATHYROIDECTOMY IN PATIENTS WITH CHRONIC KIDNEY DISEASE RRCV CMG Renal and Transplant Service
GUIDELINES FOR MAINTAINING SERUM CALCIUM FOLLOWING PARATHYROIDECTOMY IN PATIENTS WITH CHRONIC KIDNEY DISEASE RRCV CMG Renal and Transplant Service 1. Introduction Secondary hyperparathyroidism is an important
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationControlling your Phosphate Intake: Step 1
University Teaching Trust Controlling your Phosphate Intake: Step Ladywell Building Dietetic Department All Rights Reserved 208. Document for issue as handout. Name: Dietitian: renaldietitians@srft.nhs.uk
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationPrescribing Guidelines for Oral Nutritional Supplements (ONS) for adults
Worcestershire Area Prescribing Committee Prescribing Guidelines for Oral Nutritional Supplements (ONS) for adults September 2017 Review Date September 2020 Version 3.0 1 Version Control: Version Type
More informationPrescribing Framework for Galantamine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationDietitian, Nutritionist, Nutritional Therapist or Diet Expert? A comprehensive guide to roles and functions.
Dietitian, Nutritionist, Nutritional Therapist or Diet Expert? A comprehensive guide to roles and functions. 1 Dietitians Choosing the right person to seek help and advice from can sometimes be a confusing
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationNew Medicines Profile. December 2013 Issue No. 13/04. Colestilan
New Medicines Profile December 2013 Issue. 13/04 Concise evaluated information to support the managed entry of new medicines in the NHS Summary (BindRen ) is an oral, non-absorbed, non-calcium, nonmetallic
More informationWest Midlands guidelines for managing Chronic Kidney Disease related Mineral and Bone Disorders in Haemodialysis Patients
West Midlands Renal Network West Midlands guidelines for managing Chronic Kidney Disease related Mineral and Bone Disorders in Haemodialysis Patients WMRN/Regional Bone Management Guidelines /1010/Final
More informationMonth/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Policy: Cinacalcet (Sensipar) Reference Number: CP.PHAR.61 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Sensipar) Reference Number: CP.PHAR.61 Effective Date: 05.01.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationUse of Oral Nutritional Supplements in Primary Care Version 1 September 2017
Use of Oral Nutritional Supplements in Primary Care Version 1 September 2017 VERSION CONTROL Version Date Amendments made Version 1 Sept 2017 New document. AG. Contents Page 2. Introduction 2. Malnutrition
More informationGood Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes
Good Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes This good practice guidance is intended to be used as a framework for care home managers to adapt when writing their
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Guideline (2010) Chronic Kidney Disease CKD: Executive Summary of Recommendations (2010) Executive Summary of Recommendations Below are the major recommendations
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationChronic Kidney Disease Mineral Bone Disorder (CKD-MBD)
Oxford Kidney Unit Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD) Information for patients This leaflet will provide you with information about chronic kidney disease mineral bone disorder (CKD-MBD)
More informationACCREDITATION APPLICATION FOR COUNCIL ON RENAL NUTRITION ACTIVITIES
ACCREDITATION APPLICATION FOR COUNCIL ON RENAL NUTRITION ACTIVITIES The following provides a step-by-step overview of how to submit your Local Chapter s activity for accreditation through the NKF National
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More informationAppropriate Use of Prescribed Oral Nutritional Supplement (ONS) in the Community
Appropriate Use of Prescribed Oral Nutritional Supplement (ONS) in the Community Aim This guideline sets out a recommended procedure for the identification and treatment of malnutrition to ensure Oral
More informationROYAL WOLVERHAMPTON HOSPITALS NHS TRUST
ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST SHARED CARE PROTOCOL FOR ERYTHROPOIETIN USE 2016 New Cross Hospital Dr J Odum Dr P B Rylance Dr P Carmichael Dr S Acton Dr B Ramakrishna Walsall Manor Hospital Dr
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationBNF 9: Blood and Nutrition
FORMULARY CHOICE RESTRICTED 1 Blood and Blood-Forming Organs 1.1 Anaemias Epoetins Epoetinalfa pre-filled (Eprex ) 1,000unit 2,000unit 3,000unit 4,000unit 5,000unit 6,000unit 8,000unit 10,000unit 20,000unit
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPARSABIV (etelcalcetide)
PARSABIV (etelcalcetide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationSurvivorship Guidelines. September 2013 (updated August 2015)
Survivorship Guidelines September 2013 (updated August 2015) CONTENTS Contents 1 Introduction... 3 2 Background... 3 3 Recommendations and Rationale... 4 Appendix 1: Holistic Needs Assessment... 9 Appendix
More informationKidney damage with normal or increased GFR Kidney damage with mild reduction in GFR
CHRONIC KIDNEY DISEASE Contents Stages of Chronic Kidney Disease Dosing adjustments Hyperphosphataemia management Secondary hyperparathyroidism Anaemias Hyperkalaemia Acidosis Hypertension STAGES OF CHRONIC
More informationConsultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off
Policy For The Adjustment Of Insulin Injections By Paediatric Diabetes Specialist Nurses/Community Paediatric Nurses Diabetes Working With Children Within NHS Grampian Co-ordinators: Lead Paediatric Diabetes
More informationCowen Healthcare Conference March 12, 2018
Cowen Healthcare Conference March 12, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationTrust Protocol for the Administration of Intravenous Methylprednisolone for Thyroid Eye Disease A Protocol. The Clinical Investigation Unit (CIU)
A Protocol For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name and job title of document author s Line Manager: Supported by:
More informationCORNWALL & IoS GUIDELINE FOR THE MANAGEMENT OF VITAMIN D DEFICIENCY& INSUFFICIENCY IN ADULTS
CORNWALL & IoS GUIDELINE FOR THE MANAGEMENT OF VITAMIN D DEFICIENCY& INSUFFICIENCY IN ADULTS INTRODUCTION Vitamin D is essential for skeletal growth and bone health. Dietary sources in the UK are very
More informationOxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer
Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer Category: Summary: Guideline Adjuvant Bisphosphonate treatment for Post-Menopausal
More informationGuideline for the Prescribing of Oral Nutritional Supplements in Adults (NUT2)
Guideline for the Prescribing of Oral Nutritional Supplements in Adults (NUT2) Author Medicines Optimisation Team, Sunderland CCG Approved by Sunderland Medicines Optimisation and Guideline Group Current
More informationChapter 25: Interactions of Dialysis Teams With Geriatricians
Chapter 25: Interactions of Dialysis Teams With Geriatricians Nicole Stankus* and Kellie Campbell *Section of Nephrology, University of Chicago, Chicago, Illinois; and Section of Geriatrics, University
More informationConsultation Group: Lead Community Dietitians Aberdeen, Aberdeenshire and Moray CHP. Review Date: October Uncontrolled when printed.
Policy For The Prescribing and Administration Of Oral Nutritional Supplements In Adults By General Practitioners And Primary Care Staff Working Within NHS Grampian Co-ordinators: Dietetic Prescribing Advisor,
More informationMedicines Formulary Blood and electrolyte disorders, and vitamin deficiencies
Medicines Formulary Blood and electrolyte disorders, and vitamin deficiencies Contents: Blood disorders 1 1. Anaemia 2 A. Non-renal patients 2 B. Patients with chronic kidney disease under the care of
More informationVitamin and Mineral Supplementation and Monitoring. Bariatric Surgery
Vitamin and Mineral Supplementation and Monitoring Bariatric Surgery We put our patients first by working as one team; leading and listening, and striving for the best. Together, we make the difference.
More informationPALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE. Chief Pharmacist. Chief Pharmacist
REFERENCE NUMBER: PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE AREA: NAME OF RESPONSIBLE COMMITTEE / INDIVIDUAL NAME OF ORIGINATOR / AUTHOR Trust-wide Chief Pharmacist Chief Pharmacist DATE
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationCalcium Management for Patients Receiving Extended Duration Hemodialysis
Calcium Management for Patients Receiving Extended Duration Hemodialysis Created November 2017; Updated March 2018 Approved by the BCPRA Home Hemodialysis Committee Table of Contents 1.0 Practice Standard...1
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationNHSG/Pol/OralNut/MGPG639
Title: Identifier: Policy And Procedure For General Practitioners And Primary Care Staff For Managing Malnutrition And Prescribing Oral Nutritional Supplements In Adults NHSG/Pol/OralNut/MGPG639 Replaces:
More informationPediatric Nutrition and Kidney Disease
Pediatric Nutrition and Kidney Disease Loai Eid, MD, MSHS, FAAP Consultant Pediatric Nephrologist Pediatric Nephrology & Hypertension Division Chief Dubai Hospital - DHA 26 th October, 2017 Objectives
More informationSouth Tyneside Exercise Referral and Weight Management Programme
South Tyneside Exercise Referral and Weight Management Programme Referral Guidance Document 2011/2012 1 2 South Tyneside Exercise Referral and Community Weight Management Programme Introduction An Exercise
More informationSERVICE SPECIFICATION 6 Conservative Management & End of Life Care
SERVICE SPECIFICATION 6 Conservative Management & End of Life Care Table of Contents Page 1 Key Messages 2 2 Introduction & Background 2 3 Relevant Guidelines & Standards 2 4 Scope of Service 3 5 Interdependencies
More informationGood Practice Guidance on Covert Administration of Medication
Good Practice Guidance on Covert Administration of Medication This good practice guidance is intended to be used as a framework for care home managers and domiciliary care providers in drawing up their
More informationQuick reference guide to prescribing adults oral nutritional supplements (ONS)
Quick reference guide to prescribing adults oral nutritional supplements (ONS) Produced by the Medicines Management Team, West Suffolk Clinical Commissioning Group in conjunction with the Dietitians, West
More informationHaemodialysis Blood Results
Haemodialysis Blood Results Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient information leaflets.htm Introduction
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationClinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet:
Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: Results of a prospective randomized controlled study Forni Valentina¹, Pruijm Menno¹,
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationDear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM
Directorate of Chief Medical Officer T: 0131-244 6930 E: john.mitchell4@gov.scot Dear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM Lithium is a
More informationSafe and effective prescribing of nutrition: the impact of dietitian prescribing rights in New Zealand
Safe and effective prescribing of nutrition: the impact of dietitian prescribing rights in New Zealand Tory Crowder, Clinical Dietitian Christchurch Hospital, Canterbury District Health Board THANKYOU
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Renvela 2.4 g powder for oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 2.4 g sevelamer carbonate.
More informationNursing in Scotland. Glasgow & Clyde Weight Management Service
Nursing in Scotland Glasgow & Clyde Weight Management Service Contact: Dr Marie L Prince Chartered Clinical Psychologist marie.prince@ggc.scot.nhs.uk GCWMS Ward 23 Surgical Block Glasgow Royal Infirmary
More informationOxford Kidney Unit What do my blood and dialysis results mean? Information for patients
Oxford Kidney Unit What do my blood and dialysis results mean? Information for patients page 2 If you are on haemodialysis (HD) or peritoneal dialysis (PD) this leaflet is for you. It will provide you
More informationPalliative and End of Life Care in End Stage Renal Disease
Palliative and End of Life Care in End Stage Renal Disease Palliative and End of Life Care Priority for Action Regional Consensus Workshop 30.06.2010 Neal Morgan Consultant Nephrologist SHSCT Outline Introduction
More informationChronic Kidney Disease in Primary Care
Clinical Stream Chronic Kidney Disease in Primary Care Dr Gerald Waters Dr Gerald Waters Renal Physician Chronic Kidney Disease Chronic Kidney Disease Normal functions of Kidneys Management of CKD Drugs
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationdietitian? nutritionist?
dietitian? nutritionist? nutrition therapist? diet expert? Registered Dietitians (RDs) are the only qualified health professionals that assess, diagnose and treat diet and nutrition problems at an individual
More informationThis letter authorises the extended use of the following guidance until 1st June 2019:
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date: 13Th November 2018 Our Ref: FA_ONS_Guide/MGPG/Nov18 Enquiries to: Frances Adamson Extension: 56689 Direct Line:
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationSWINDON PCT CATARACT DIRECT REFERRAL SCHEME SERVICE LEVEL AGREEMENT
SWINDON PCT CATARACT DIRECT REFERRAL SCHEME SERVICE LEVEL AGREEMENT PROTOCOL This document sets out the details of the administrative protocol for the direct referral by Optometrists/OMPs of cataract patients.
More informationGuidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationPrescribing Framework for Naltrexone in Alcohol Relapse Prevention
Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient
More information